Recombinant rhabdovirus encoding for CCL21

A composition comprising a recombinant vesicular stomatitis virus encoding in its genome a vesicular stomatitis virus nucleoprotein (N), large protein (L), phosphoprotein (P), matrix protein (M), glycoprotein (G) wherein, the gene coding for the glycoprotein G of the vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV, wherein the VSV does not include within its genome an additional cargo, and wherein

• the nucleoprotein (N) comprises an amino acid as set forth in SEQ ID NO:7 or a functional variant at least=98% identical to SEQ ID NO:7,
• the phosphoprotein (P) comprises an amino acid as set forth in SEQ ID NO:8 or a functional variant at least=98% identical to SEQ ID NO:8,
• the large protein (L) comprises an amino acid as set forth in SEQ ID NO:9 or a functional variant at least=98% identical to SEQ ID NO:9,
• the matrix protein (M) comprises an amino acid as set forth in SEQ ID NO:10 or a functional variant at least=98% identical to SEQ ID NO:10, and
• a PD-1 pathway inhibitor, wherein the PD-1 pathway inhibitor is an antagonistic antibody which is directed against PD-1
• wherein said composition of said recombinant vesicular stomatitis virus is administered concomitantly, sequentially or alternately with the antagonistic antibody against PD-1.